Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‐Vec in Ovarian Cancer
· genelux corporation
AI Briefing
- • Genelux announces publication of translational analysis on Olvi-Vec's effect in ovarian cancer treatment.
- • Analysis supports clinical outcomes of reversing platinum resistance in Phase 2 trial.
- • Study provides mechanistic support for Olvi-Vec's immune activation and chemotherapy sensitization effects.
Context
Genelux has announced the publication of a translational analysis. The analysis supports immune activation and chemotherapy sensitization with Olvi-Vec in ovarian cancer.
The findings provide support for previously reported clinical outcomes from the Phase 2 VIRO-15 trial, which showed reversal of platinum resistance or refractoriness.
Advertisement